Jiankang Hu
P.R. China
Pingxiang, China
Pingxiang, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 28 publications
High baseline neutrophil-to-lymphocyte ratio is associated with better adalimumab response in patients with rheumatoid arthritis.
Journal: The Journal of international medical research
Published: June 18, 2026
Vunakizumab for Radiographic Axial Spondyloarthritis: A Randomized Clinical Trial.
Journal: JAMA network open
Published: May 08, 2026
Efficacy and Safety of Firsekibart in Patients with Acute Gout Unsuitable for Standard Therapy: 48-Week Results from an Open-Label Extension of a Randomized Phase 3 Trial.
Journal: Advances in therapy
Published: February 13, 2026
Efficacy and safety of Xeligekimab (GR1501) in the treatment of axial Spondyloarthritis: Results from a Phase II clinical trial.
Journal: Rheumatology and immunology research
Published: October 31, 2025
Xeligekimab, an Interleukin-17A Antagonist for Active Radiographic Axial Spondyloarthritis in Chinese Patients: 16- and 48-Week Results from a Phase III, Randomized, Double-Blind, Placebo-Controlled Study.
Journal: BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy
Published: October 28, 2025
Evaluation of the Safety, Tolerability, Pharmacokinetics, and Efficacy of Subcutaneous Firsekibart in Gout: A Phase Ib/II Clinical Trial.
Journal: International journal of rheumatic diseases
Published: October 17, 2025
A Phase 3 Trial of Telitacicept for Systemic Lupus Erythematosus.
Journal: The New England journal of medicine
Published: October 15, 2025
Efficacy of Ixekizumab in Chinese Patients with Radiographic-Axial Spondyloarthritis by Baseline Inflammation Status on Magnetic Resonance Imaging.
Journal: Rheumatology and therapy
Published: September 09, 2025
Efficacy and safety of secukinumab in patients with active psoriatic arthritis at Week 16 and up to 52 weeks: Results from a Phase III, randomized, double-blind, placebo-controlled bridging study in China.
Journal: Chinese medical journal
Published: September 07, 2025
Efficacy and Safety of Firsekibart Compared to Etoricoxib for Gout Flares: A Phase 2, Multicenter, Open-label, Active-controlled, Randomized Non-inferiority Trial.
Journal: Rheumatology and therapy
Published: June 30, 2025
Firsekibart as a Prophylactic Treatment for Acute Gout Flare in Participants Initiating Urate-Lowering Therapy: A Phase 2, Randomized, Open-Label, Multicenter, Active-Controlled Trial.
Journal: ACR open rheumatology
Published: April 22, 2025
Last Updated: 09/26/2026